Novartis suspends two cancer therapies over quality concerns
Zurich: Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing."Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply in the next six weeks", the...
Login or Register to read the full article
Zurich: Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.
"Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply in the next six weeks", the Swiss company said.
The drugmaker added in a statement that some doses of cancer therapy Lutathera would be available in Europe and Asia from a site in Spain, but there might be some delays in supply.
Lutathera and Pluvicto are both so-called radioligand therapies, a type of treatment that uses nuclear medicine to precisely target and treat cancer cells.
Read also: Novartis to cut thousands of jobs in global revamp: Sources
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd